in the absence of a submission from the holder of the marketing authorisation
metformin hydrochloride (Glucophage SR®) is not recommended for use within NHS Scotland.
Indication under review: Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are:
• at high risk for developing overt type 2 diabetes mellitus and
• still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice190KB (PDF)
Medicine details
- Medicine name:
- metformin hydrochloride (Glucophage)
- SMC ID:
- 1308/18
- Indication:
- Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are: • at high risk for developing overt type 2 diabetes mellitus and • still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 15 January 2018